Continuously pioneering innovation and accelerating product launch. As ProteinT's proteomics-centered multi-omics technologies continue to break through, multiple products have entered the registration filing process. To accelerate commercialization and successfully translate its self-developed series of products as early as possible, on October 15, 2022, ProteinT signed a cooperation agreement with Zhixin Incubator. Leveraging the incubator's relevant experience and strengths, the partnership will speed up the product registration process and bring to market as early as possible multiple products based on proteomics and nuclear magnetic resonance technologies, delivering more convenient, accurate, and affordable products for tumor early screening, companion diagnostics, and chronic disease management.

Signing ceremony: Sun Lin, Brand Director of ProteinT, and Yang Li, Investment Promotion and Registration Director of Zhixin Incubator

ProteinT is committed to being a leader in clinical proteomics and has long been deeply engaged in the gene-protein-metabolism multi-omics field. At the end of 2021, ProteinT's core R&D team overcame the technical bottleneck in the clinical application of proteomics. Its self-developed next-generation liquid biopsy technology achieved the identification and quantitative analysis of 4,000+ blood proteins per single sample within a unit hour. At present, ProteinT is developing and launching product pipelines covering early screening and early diagnosis of common cancers (such as liver cancer, lung cancer, gastric cancer, esophageal cancer, colorectal cancer, and pancreatic cancer), pan-cancers, and chronic diseases such as cardiovascular and cerebrovascular diseases, as well as tumor recurrence monitoring and drug companion diagnostics. As R&D progresses, multiple products are gradually entering the registration process. To focus on technological breakthroughs and product development, ProteinT hopes to leverage the service provider's experience to accelerate product registration and commercialization.

ProteinT

As a national-level professional medical incubator, Zhixin (Tianjin) Technology Business Incubator has cumulatively served more than 100 enterprises and has extensive experience in medical device business licenses, product licenses, production licensing services, production system establishment services, testing commissioning services, and intellectual property patent registration. It has also signed cooperation agreements with the Tianjin Medical Products Administration Registration and Evaluation Center and the Huaming High-tech Zone Management Committee, was approved as the Tianjin Medical Device Evaluation and Inspection Center, and became an extension window for registration and evaluation services. It can step in at the R&D stage, the testing and inspection stage, the clinical trial stage, and the pre-acceptance rapid review stage, achieving early intervention and early correction throughout the registration process. It builds a fast-track review channel for medical devices, saving enterprises 2-3 years of registration time.

Advancing medicine through continuous technological innovation. ProteinT has been deeply engaged in the proteomics-centered multi-omics field for many years, continuously breaking through existing technical bottlenecks. Multiple R&D pipelines are being advanced in parallel, and related products are successively entering the registration filing stage. With the signing of this cooperation with Zhixin Incubator, the product registration process will be greatly accelerated, and the timeline for product translation and launch is expected to be pushed forward once again, making it possible for proteomics technology to be applied to clinical practice at an earlier date and delivering more precise, more convenient, and more accessible tumor screening and chronic disease management that benefits more patients.